UAE approves Sinopharm’s protein-based vaccine

The vaccine will be produced and distributed by a joint venture between the UAE's Group 42 and China National Biotec Group (CNBG), a unit of China National Pharmaceutical Group (Sinopharm)

The United Arab Emirates (UAE) has approved emergency use of Sinopharm’s protein-based COVID-19 vaccine and it will be available to the public as a booster dose starting January 2022, the health ministry said.

The vaccine will be produced and distributed by a joint venture between the UAE’s Group 42 and China National Biotec Group (CNBG), a unit of China National Pharmaceutical Group (Sinopharm), the ministry said in a statement on state media yesterday.

The approval came following a UAE-based study that included individuals who were previously vaccinated with two doses of Sinopharm CNBG’s inactivated vaccine, the ministry added.

Edits by EP News Bureau

China National Biotec GroupCovid 19 vaccineSinopharm COVID vaccine
Comments (0)
Add Comment